Liver-Targeted Alzheimer's Gene Therapy
Key Questions
What is the liver-targeted Alzheimer's gene therapy?
The APOE3Ch gene therapy is delivered intravenously to the liver, where it clears amyloid plaques from mouse brains without crossing the blood-brain barrier. It improved cognition in preclinical mouse studies.
What results were seen in the mouse studies?
Mice treated with the liver-targeted gene therapy showed reduced brain amyloid buildup, a hallmark of Alzheimer’s. This led to better cognitive performance without direct brain delivery.
What are the next steps for this therapy?
Primate trials are upcoming following promising mouse results. The approach holds potential for human use in extending healthspan by addressing Alzheimer’s pathology.
APOE3Ch gene therapy delivered to liver clears amyloid from mouse brains without crossing BBB, improving cognition; primate trials upcoming, potential for human healthspan extension.
Sources (2)
Updated May 9, 2026